EMCC European Monitoring Centre on Change

Novo Nordisk Production

Company/Organisation:
Novo Nordisk Production

Geographic Location

Country: France
Region: Eure-et-Loir; Centre; Bassin Parisien
Location of affected unit(s): Chartres

Company

Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21.20 - Manufacture of pharmaceutical preparations
Number Employed: 1200
Group: Novo Nordisk

Employment Effects

Announcement Date: 05-09-2018
Type of Restructuring: Business expansion
Employment Effect Start: 15-09-2018
Foreseen End Date: 31-12-2021
Planned Job Creation: 100

Additional Information

Novo Nordisk, the Danish pharmaceutical group that is the world leader in the treatment of diabetes, has announced the recruitment of 100 employees for its site at Chartres (Eure-et-Loir). After several waves of hiring the last years (250 job creations in 2016, 150 job creations in 2013), the site opens a new recruitment campaign of 100 positions and announces a project to expand the plant. Novo Nordisk already has 1,200 employees on site. A first hiring period is planned for half of the new employees to recruit operators, regulators, line drivers and technicians. It will last until the end of the year.

A second phase of hiring focuses air handling engineers, process engineers, building engineers and computer scientists. It will follow the construction of two new production lines by March 2019. The hiring will concern the department of Eure-et-Loire, but will be extended to the region Center-Loire Valley and the Parisian region, and then to the whole France. Novo Mordisk will work closely with the public employment service (Pôle Emploi) and will broadcast ads on internal networks and social networks.

Sources: